Home > Name List By other > (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10, 10a-tetrahydro-6aH-benzo[c]chromen-9-one

CAS No 51022-71-0 , (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,
10a-tetrahydro-6aH-benzo[c]chromen-9-one

  • Name: (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,
    10a-tetrahydro-6aH-benzo[c]chromen-9-one
  • Synonyms: SureCN33339; CHEBI:189797; Nabilone (USAN/INN); CHEMBL947;(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,
    10a-tetrahydro-6aH-benzo[c]chromen-9-one; Cesamet (TN); 51022-71-0; AC1NR4QM; DAP000067;Cesamet;
  • CAS Registry Number:
  • Flash Point: 145.4 °C
  • Boiling Point: 457.4 °Cat760mmHg
  • Density: 1.029 g/cm3
  • Refractive index: 1.516
  • Water Solubility: DMSO: ~18 mg/mL, soluble
  • Safety Statements: 36/37/39-45
  • Hazard Symbols: Xn: Harmful;
  • Flash Point: 145.4 °C
  • Molecular Weight: 372.54084
  • InchiKey: GECBBEABIDMGGL-RTBURBONSA-N
  • InChI: InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,
    3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,
    18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
  • Risk Statements: 22
  • Molecular Formula: C24H36O3
  • Molecular Structure:CAS No:51022-71-0 (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,<br />10a-tetrahydro-6aH-benzo[c]chromen-9-one

Related products

Search by region :

Select to

51022-71-0 Nabilone

  • Nabilone, Min 99%
  • China Finechemie Co., Ltd. [Manufacturer]
  • Tel: +86-23-99186710
  • Fax: +86-23-99186729
  • Address: 28th Floor Mordern Building,New-Tech Zone400020 ChongqingCHINA Chongqing,nullChina
Contact Supplier

51022-71-0 Nabilone

Contact Supplier

51022-71-0 Nabilone

  • China ZHEJIANG HOLYPHARM BIOTECH CO.,LTD [Manufacturers]
  • Tel: 86-533-8585678
  • Fax: 86-57187357695
  • Address: Room C 13th Floor, West Wing International Garden, No.160 Tianmushan Road, Xihu District, Hangzhou City, China null,nullChina
Contact Supplier

51022-71-0 9H-Dibenzo[b,d]pyran-9-one,3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-,(6aR,10aR)-rel-

Contact Supplier

51022-71-0 Nabilone

  • China Wuhan Canaimex Inc., Ltd [Manufacturers]
  • Tel: +86-(27)-84254492
  • Fax: +86-(27)-84254492
  • Address: 4/F Block 16, Hi-Tech Industrial Park, Wuhan Economic & Technological Development Zone, Wuhan, Hubei 430056, wuhan,hubeiChina
Contact Supplier

51022-71-0 9H-Dibenzo[b,d]pyran-9-one,3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-,(6aR,10aR)-rel-

  • China SOGA ENTERPRISES ASIA GROUP [Manufacturers]
  • Tel: +86-633-8332928
  • Fax: +86-633-8352255
  • Address: No.1,Huanghai Yilu.Rizhao,Shandong null,ShandongChina
Contact Supplier

51022-71-0 Nabilone

  • NabiloneNabilone, 95%
  • Canada Dalton Pharma Services [Manufacturer]
  • Tel: 4166612102
  • Fax: 4166612108
  • Address: 349 Wildcat RoadM3J 2S3 TorontoCANADA M3J 2S3 Toronto,nullCanada
Contact Supplier

Select to

1/1
References of (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,
10a-tetrahydro-6aH-benzo[c]chromen-9-one
Title: Nabilone
CAS Registry Number: 51022-71-0
CAS Name: (6aR,10aR)-rel-3-(1,1-Dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one
Manufacturers' Codes: LY-109514
Trademarks: Cesamet (Lilly)
Molecular Formula: C24H36O3
Molecular Weight: 372.54
Percent Composition: C 77.38%, H 9.74%, O 12.88%
Literature References: Synthetic cannabinoid with antiemetic, antiglaucoma, and CNS activity. Prepn: R. A. Archer, DE 2451934, idem, US 3968125 (1975, 1976 both to Lilly); R. A. Archer et al., J. Org. Chem. 42, 2277 (1977). Pharmacology: P. Stark, R. A. Archer, Pharmacologist 17, 210 (1975); R. M. Orzelek-O'Neil et al., Toxicol. Appl. Pharmacol. 54, 493 (1980). Physiological disposition: A. Rubin et al., Clin. Pharmacol. Ther. 22, 85 (1977). Pharmacokinetics: H. R. Sullivan et al., Biomed. Mass Spectrom. 5, 296 (1978). Behavioral effects: P. Stark, P. B. Dews, J. Pharmacol. Exp. Ther. 214, 124 (1980). Clinical studies as antiemetic in cancer patients: N. Steele et al., Cancer Treat. Rep. 64, 219 (1980); C. J. Williams et al., Cancer Clin. Trials 3, 363 (1980). Clinical evaluation of anxiolytic effects: L. F. Fabre et al., J. Clin. Pharmacol. 21, Suppl 8-9, 377S (1981); R. M. Glass et al., ibid. 383S. Review of pharmacology and efficacy as antiemetic: A. Ward, B. Holmes, Drugs 30, 127-144 (1985). Toxicity study in neonatal rats: C. L. Moss et al., Toxicol. Appl. Pharmacol. 48, A120 (1979). Comprehensive description: R. W. Souter, Anal. Profiles Drug Subs. 10, 499-512 (1981).
Properties: White crystals from ethyl acetate/hexane, mp 159-160°. uv max (ethanol): 207, 280 nm (e 47000, 250). pKa in 66% DMF: 13.5.
Melting point: mp 159-160°
pKa: pKa in 66% DMF: 13.5
Absorption maximum: uv max (ethanol): 207, 280 nm (e 47000, 250)
NOTE: This is a controlled substance (hallucinogen): 21 CFR, 1308.12.
Therap-Cat: Antiemetic.
Keywords: Antiemetic.